Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Buparlisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 944396-07-0, Nvp-bkm120, Bkm120, 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine, Nvp-bkm-120, Bkm-120
    Molecular Formula
    C18H21F3N6O2
    Molecular Weight
    410.4  g/mol
    InChI Key
    CWHUFRVAEUJCEF-UHFFFAOYSA-N
    FDA UNII
    0ZM2Z182GD
    Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
    2.1.2 InChI
    InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
    2.1.3 InChI Key
    CWHUFRVAEUJCEF-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
    2.2 Other Identifiers
    2.2.1 UNII
    0ZM2Z182GD
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bkm120

    2. Nvp-bkm120

    2.3.2 Depositor-Supplied Synonyms

    1. 944396-07-0

    2. Nvp-bkm120

    3. Bkm120

    4. 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

    5. Nvp-bkm-120

    6. Bkm-120

    7. 1202777-78-3

    8. Bkm 120

    9. Buparlisib (bkm120)

    10. Nvp-bkm 120

    11. Bkm120 (nvp-bkm120, Buparlisib)

    12. 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

    13. Bkm-120nx

    14. Bkm120-nx

    15. 5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine

    16. 0zm2z182gd

    17. Chembl2017974

    18. Chebi:71954

    19. 944396-07-0 (free Base)

    20. 2-pyridinamine,5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-

    21. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.

    22. Buparlisib [inn]

    23. Buparlisib [usan:inn]

    24. Unii-0zm2z182gd

    25. Bkm 120nx

    26. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine

    27. Sd5

    28. Buparlisib; Bkm120

    29. 3sd5

    30. Buparlisib (usan/inn)

    31. Buparlisib [usan]

    32. Buparlisib [who-dd]

    33. Mls006010984

    34. Schembl146956

    35. Gtpl7878

    36. Bkm120,nvp-bkm120

    37. Ammd00049

    38. Bkm-120 (pi3k)

    39. Dtxsid50241486

    40. Ex-a189

    41. Hms3295i15

    42. Hms3655d16

    43. Bkm120 (nvp-bkm120)

    44. Bkm120 - Nvp-bkm120

    45. Bdbm50380363

    46. Mfcd18251596

    47. Nsc754353

    48. Nsc799370

    49. S2247

    50. Zinc43154039

    51. 2-pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-

    52. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyridinamine

    53. Akos016005372

    54. Am85983

    55. Bcp9001011

    56. Ccg-264954

    57. Cs-0089

    58. Db11666

    59. Nsc-754353

    60. Nsc-799370

    61. Sb16577

    62. Ncgc00262604-01

    63. Ncgc00262604-08

    64. Ac-32077

    65. Ac-35575

    66. As-40568

    67. Hy-70063

    68. Smr004702786

    69. Db-079882

    70. Ft-0755923

    71. Sw218149-2

    72. A25436

    73. D10584

    74. A892274

    75. J-516601

    76. Brd-k42191735-001-01-2

    77. Q25100534

    78. 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine

    79. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

    80. 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine

    2.4 Create Date
    2007-08-09
    3 Chemical and Physical Properties
    Molecular Weight 410.4 g/mol
    Molecular Formula C18H21F3N6O2
    XLogP31.5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count11
    Rotatable Bond Count3
    Exact Mass410.16780842 g/mol
    Monoisotopic Mass410.16780842 g/mol
    Topological Polar Surface Area89.6 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity530
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1